Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02683928 · ClinicalTrials.gov registry record · Phase 2
To Assess the Safety and Activity of GBR 830, Compared to Placebo, in Adults With Moderate-to-severe Atopic Dermatitis
A Phase 2 study of Atopic Dermatitis, sponsored by Ichnos Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 17
- Study locations
NCT02683928: Completed Phase 2 study of Atopic Dermatitis, sponsored by Ichnos Sciences.
NCT02683928 is a Phase 2 study of Atopic Dermatitis that has completed, run by Ichnos Sciences. The registered enrollment target is 64 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (89% lower). The trial reports 17 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02683928, a Phase 2 study of Atopic Dermatitis, has completed, sponsored by Ichnos Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 17
- Study locations
Study Summary
The purpose of this study is to determine the effect of GBR 830 on biomarkers in atopic dermatitis to enable further studies in this indication.
Primary Outcome
A treatment-emergent adverse event (TEAE) was defined as any new adverse event (AEs) or worsening of an existing condition after administration of the study drug up to and including the follow-up visit.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL GBR 830
Study Locations (17)
Ontario
- Glenmark Investigational Site 8 - Markham
- Glenmark Investigational Site 7 - Peterborough
- Glenmark Investigational Site 6 - Richmond Hill
- Glenmark Investigational Site 10 - Waterloo
Texas
- Glenmark Investigational Site 2 - Dallas
- Glenmark Investigational Site 17 - Katy
- Glenmark Investigational Site 12 - Webster
California
- Glenmark Investigational Site 5 - Los Angeles
- Glenmark Investigational Site 3 - San Diego
Arkansas
- Glenmark Investigational Site 14 - Rogers
Florida
- Glenmark Investigational Site 15 - Tampa
Missouri
- Glenmark Investigational Site 11 - St Louis
New Jersey
- Glenmark Investigational Site 16 - Berlin
New York
- Glenmark Investigational Site 1 - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2016-03 |
| Est. Completion | 2017-06 |
| Phase | Phase 2 |
What the finished NCT02683928 record still lists
NCT02683928 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02683928 lists 17 locations in 11 states (Ontario, Texas, California).
Frequently Asked Questions
What is clinical trial NCT02683928 about?
NCT02683928 is a clinical study titled "To Assess the Safety and Activity of GBR 830, Compared to Placebo, in Adults With Moderate-to-severe Atopic Dermatitis". The purpose of this study is to determine the effect of GBR 830 on biomarkers in atopic dermatitis to enable further studies in this indication.
What is the current status of trial NCT02683928?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2016-03. Estimated completion is 2017-06.
What conditions does trial NCT02683928 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT02683928?
The interventions under investigation include: Placebo (BIOLOGICAL), GBR 830 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02683928?
This trial is sponsored by Ichnos Sciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02683928 being conducted?
This trial has 17 study locations across Arkansas, California, Florida, Missouri, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02683928's enrollment target sits among peer trials
64 103rd of 150 higher than 48 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study Evaluating TRIV-509 in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia